# Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

> **NCT00365157** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 132 (actual)

## Conditions studied

- Advanced Urothelial Carcinoma
- Locally Advanced Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- Recurrent Urothelial Carcinoma
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage IV Bladder Urothelial Carcinoma AJCC v7
- Unresectable Urothelial Carcinoma

## Interventions

- **DRUG:** Eribulin Mesylate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT00365157
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2006-10-23
- **Primary completion:** 2025-07-09
- **Final completion:** 2026-07-09
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365157, "Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00365157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*